Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4JPA

Mmp13 in complex with a piperazine hydantoin ligand

Summary for 4JPA
Entry DOI10.2210/pdb4jpa/pdb
Related4JP4
DescriptorCollagenase 3, ZINC ION, CALCIUM ION, ... (6 entities in total)
Functional Keywordsmatrix metalloprotease, calcium binding, zinc binding, hydrolase
Biological sourceHomo sapiens
Cellular locationSecreted, extracellular space, extracellular matrix : P45452
Total number of polymer chains2
Total formula weight40430.34
Authors
Gerhardt, S.,Hargreaves, D. (deposition date: 2013-03-19, release date: 2014-03-05, Last modification date: 2024-03-20)
Primary citationDe Savi, C.,Waterson, D.,Pape, A.,Lamont, S.,Hadley, E.,Mills, M.,Page, K.M.,Bowyer, J.,Maciewicz, R.A.
Hydantoin based inhibitors of MMP13--discovery of AZD6605.
Bioorg.Med.Chem.Lett., 23:4705-4712, 2013
Cited by
PubMed Abstract: Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chemistry campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimising MMP13 potency, solubility and DMPK properties whilst maintaining good selectivity over MMP14. A number of high quality candidates were progressed and following rat and dog safety evaluation, AZD6605 (3m) was identified as a candidate drug.
PubMed: 23810497
DOI: 10.1016/j.bmcl.2013.05.089
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon